Epithelial ovarian cancer: Rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment

International Journal of Gynecological Cancer

Volumn 24, Issue 3, 2014, Pages 468-477

  Despierre, Evelyn ^a,b   Yesilyurt, Betül T ^b,c   Lambrechts, Sandrina ^a   Johnson, Nick ^d   Verheijen, René ^e   Van Der Burg, Maria ^f   Casado, Antonio ^g   Rustin, Gordon ^h   Berns, Els ^f   Leunen, Karin ^a   Amant, Frédéric ^a   Moerman, Philippe ^a   Lambrechts, Diether ^b   Vergote, Ignace ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f ERASMUS MC CANCER INSTITUTE   (Netherlands)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Clinical molecular genetics; Molecular biomarkers; Oncogenes; Ovarian cancer; Tumor suppressor genes

Indexed keywords

AKT3 PROTEIN; FOXL2 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; PROTEIN KINASE; PROTEIN KINASE B BETA; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXL2 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; ONCOPROTEIN; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE K RAS; ONCOGENE N RAS; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOMATIC MUTATION; STANDARD; UNIVERSITY HOSPITAL; CARCINOMA; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; OVARY TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CELL CYCLE PROTEINS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; F-BOX PROTEINS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GTP PHOSPHOHYDROLASES; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 84900436392     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000089     Document Type: Article

References (30)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-781.
2. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
3. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009;40:1213-1223.
4. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151-160
5. Hess V, A?Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-1044.
6. Crotzer DR, Sun CC, Coleman RL, et al. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007;105:404-408.
7. Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage IIYIV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108:361-368.
8. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39:D945-D950.
9. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221:49-56.
10. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.
11. de Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753-762.
12. Reumers J, de Rijk P, Zhao H, et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol. 2011;30:61-68.
13. Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by theGynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419-423.
14. Rodríguez IM, Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol. 2002;26:139-152.
15. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ?pseudomyxoma peritonei?. Am J Surg Pathol. 2000;24:1447-1464.
16. Despierre E, Lambrechts D, Neven P, et al. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol. 2010;117:358-365.
17. Steffensen KD, Waldstrom M, Grove A, et al. Improved classification of epithelial ovarian cancer: results of 3 Danish cohorts. Int J Gynecol Cancer. 2011;21:1592-1600.
18. Auner V, Kriegshäuser G, Tong D, et al. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer. 2009;9:111.
19. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003;90:378-381.
20. Song GA, Deng G, Bell I, et al. Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol. 2005;26:745-750.
21. Kelemen LE, Köbel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011;12:1071-1080.
22. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174:1597-1601
23. Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch. 2012;460:77-87.
24. Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol. 2011;225:189-194.
25. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532-1543.
26. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94:1369-1374.
27. Gustin JP, Cosgrove DP, Park BH. The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets. 2008;8:733-740.
28. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484-486.
29. Singer G, Shih IeM, Truskinovsky A, et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol. 2003;22:37-41.
30. Verbruggen MB, Sieben NL, Roemen GM, et al. v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior. Int J Gynecol Cancer. 2009;19:1560-1563.